Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
Bruker Corporation (
NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker’s continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.
Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics
Bruker Corporation (
NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed.
Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced significant further advances in ultra-high sensitivity 4D-Proteomics™ with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF® methods for key biological and clinical research problems with very low sample amounts.
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows.
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4th, 2025 at 5:30 PM Eastern Time.
Bruker Launches Revolutionary timsOmniTM Mass Spectrometer
For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy control, ion accumulation, and reaction time regulation is a cornerstone innovation of the timsOmni™ platform. This also enables CIU, further expanding the value of proteoform CCS information, followed by multiple electron-based (ECD, EID) and collision-based (CID) fragmentation techniques. The timsOmni uniquely enables protein researchers and biologics developers to tailor information-rich dissociation pathways for deeper insights - with high speed and high sensitivity.
Bruker Launches Novel timsMetabo™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) launched timsMetabo, a peak-performance 4D-Metabolomics™ mass spectrometer delivering unprecedented sensitivity, separation power and annotation confidence for small molecules, further enhanced by the novel TIMS ‘MoRE’ scan-mode. The timsMetabo system enables the generation of a ‘digital metabolome archive’ for every sample, providing TIMS-enabled qual-quant performance with greatly increased confidence for automated annotation, leveraging 4D separations and reproducible molecular collision cross sections (CCS) at scale for 4D-Metabolomics and 4D-Lipidomics™.
Bruker Introduces Novel MOVE-T System for Transferable, Robust Milk and Liquid Dairy Analysis with FT-NIR Technology
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the MOVE-T, a state-of-the-art liquid dairy analyzer designed to elevate quality control standards in the dairy industry. Utilizing advanced Fourier Transform Near-Infrared (FT-NIR) technology, the MOVE-T provides unparalleled precision analyzing raw milk and other liquid dairy products, ensuring superior product quality and consistency.
Bruker Announces Quarterly Dividend
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on June 27, 2025 to stockholders of record as of June 16, 2025.
Bruker and 10x Genomics Reach Global Settlement of Patent Litigation
Bruker Corporation (Nasdaq: BRKR) today announced that Bruker and 10x Genomics have reached a final settlement to resolve their patent disputes and dismiss multiple litigations, with global patent cross license agreements between the two companies. In connection with the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in several countries, including actions pending in the United States, in Germany, and before the European Unified Patent Court, will be withdrawn.
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To KnowA number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
2 Stocks Under $50 to Target This Week and 1 to AvoidStocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Bruker’s (NASDAQ:BRKR) Q1 Sales Top Estimates, Full-Year Outlook Slightly Exceeds ExpectationsScientific instrument company Bruker (
NASDAQ:BRKR). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 11% year on year to $801.4 million. The company’s full-year revenue guidance of $3.52 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.47 per share was 5.9% above analysts’ consensus estimates.
Bruker Reports First Quarter 2025 Financial Results
Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2025.
Bruker (BRKR) Reports Q1: Everything You Need To Know Ahead Of EarningsScientific instrument company Bruker (
NASDAQ:BRKR).
will be reporting earnings tomorrow morning. Here’s what investors should know.
Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025
Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology and multiomics research at the 2025 American Association for Cancer Research (AACR) General Meeting. These new advancements build upon the innovations announced at AGBT, including launch of CosMx WTX assay for subcellular spatial imaging of the whole transcriptome, the PaintScape™ platform for visualization of 3D genome architecture and chromosomal structure in single cells, the PowerOMX™ engine for streamlined spatial proteomics analysis on the CellScape™ platform, and the 1,200-plex protein panel for GeoMx® DSP. Bruker Spatial Biology today announces the following innovations that underscore Bruker’s leading commitment to advancing spatial biology with pioneering, best-in-class platforms.
Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop system offers an accessible entry point into live single-cell functional analysis.
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 to QuestionThe stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services StocksThe end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (
NASDAQ:ILMN) and the rest of the life sciences tools & services stocks fared in Q4.
Reflecting On Research Tools & Consumables Stocks’ Q4 Earnings: Agilent (NYSE:A)Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Agilent (
NYSE:A) and its peers.
Bruker Introduces nVista 2P Miniature Microscope
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data reconstruction, providing researchers with unprecedented insights into neuronal activity. Featuring several innovations in miniscope design, nVista 2P offers enhanced resolution for sub-cellular imaging and mapping of neural circuit dynamics.
